Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378:158-168.
Haanen J, Carbonnel F, Robert C, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28:iv119-iv142.
Manns MP, Czaja AJ, Gorham JD, et al. Diagnosis and management of autoimmune hepatitis. Hepatology. 2010;51:2193-2213.
Kwo PY, Cohen SM, Lim JK. ACG clinical guideline: Evaluation of abnormal liver chemistries. Am J Gastroenterol. 2017;112:18-35.
Brahmer JR, Lacchetti C, Schneider B, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2018. doi:10.1200/JCO.2017.77.6385. [Epub ahead of print].
Puzanov I, Diab A, Abdallah K, et al. Managing toxicities associated with immune checkpoint inhibitors: Consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer. 2017;5:95.
De Martin E, Michot JM, Papouin B, et al. Liver injury from cancer immunotherapy using monoclonal immune checkpoint inhibitors. J Hepatol. 2018. doi:10.1016/j.jhep.2018.01.033. [Epub ahead of print].
National Institutes of Health. LiverTox: Clinical and research information on drug-induced liver injury. https://livertox.nlm.nih.gov//Infliximab.htm. Accessed April 12, 2018.
Santini FC, Rizvi H, Wilkins O, et al. Safety of retreatment with immunotherapy after immune-related toxicity in patients with lung cancers treated with anti-PD(L)-1 therapy. [ASCO abstract 9012]. J Clin Oncol. 2017;35(suppl).
Ziemer M, Koukoulioti E, Beyer S, et al. Managing immune checkpoint-inhibitor-induced severe autoimmune-like hepatitis by liver-directed topical steroids. J Hepatol. 2017;66:657-659.
Schadendorf D, Wolchok JD, Hodi FS, et al. Efficacy and safety outcomes in patients with advanced melanoma who discontinued treatment with nivolumab and ipilimumab because of adverse events: a pooled analysis of randomized phase II and III trials. J Clin Oncol. 2017;34:3807-3814.
El-Khoueiry AB, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet. 2017;389:2492-2502.

As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.

Moderator

Joshua Bauml, MD

Assistant Professor, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania

Disclosures

Disclosure: Joshua Bauml, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Celgene Corporation; Clovis Oncology; Genentech, Inc.; Guardant Health; Merck & Co., Inc.
Received grants for clinical research from: Bayer HealthCare; Carevive Systems; Clovis Oncology; Janssen Pharmaceuticals; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation

Dr Bauml does intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr Bauml does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Panelist

Richard S. Kalman, MD

Assistant Professor, Sidney Kimmel Medical College, Philadelphia, Pennsylvania

Disclosures

Disclosure: Richard S. Kalman, MD, has disclosed no relevant financial relationships.

Dr Kalman does intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr Kalman does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Editor

Charlotte Warren

Senior Scientific Director, Medscape, LLC

Disclosures

Disclosure: Charlotte Warren has disclosed no relevant financial relationships.

CME Reviewer

Amy H. Seung, PharmD, BCOP

Disclosures

Disclosure: Amy H. Seung, PharmD, BCOP, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: BeyondSpring Pharmaceuticals

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.

CME / ABIM MOC

Clinical Pearls on the Management of Immune-Mediated AEs Affecting the Liver

Authors: Joshua Bauml, MD; Richard Kalman, MD
CME / ABIM MOC Released: 5/23/2018
THIS ACTIVITY HAS EXPIRED FOR CREDIT
Valid for credit through: 5/23/2019, 11:59 PM EST

Start Activity

Target Audience and Goal Statement

This activity is intended for gastroenterologists, oncologists, and emergency medicine physicians.

The goal of this activity is to discuss the identification and management of immune-mediated hepatitis related to treatment with immune checkpoint blockade therapy.

Upon completion of this activity, participants will:

Have increased knowledge regarding the
- Common immune-mediated adverse events (imAEs) in patients receiving an immune checkpoint inhibitor regimen
Have greater competence related to
- Mitigation of imAEs in patients receiving an immune checkpoint inhibitor regimen
- Communication regarding imAEs between members of the multidisciplinary and oncology care teams

Disclosures

Moderator

Joshua Bauml, MD

Assistant Professor, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania

Disclosures

Disclosure: Joshua Bauml, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Celgene Corporation; Clovis Oncology; Genentech, Inc.; Guardant Health; Merck & Co., Inc.
Received grants for clinical research from: Bayer HealthCare; Carevive Systems; Clovis Oncology; Janssen Pharmaceuticals; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation

Dr Bauml does intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr Bauml does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Panelist

Richard S. Kalman, MD

Assistant Professor, Sidney Kimmel Medical College, Philadelphia, Pennsylvania

Disclosures

Disclosure: Richard S. Kalman, MD, has disclosed no relevant financial relationships.

Dr Kalman does intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr Kalman does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Editor

Charlotte Warren

Senior Scientific Director, Medscape, LLC

Disclosures

Disclosure: Charlotte Warren has disclosed no relevant financial relationships.

CME Reviewer

Amy H. Seung, PharmD, BCOP

Disclosures

Disclosure: Amy H. Seung, PharmD, BCOP, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: BeyondSpring Pharmaceuticals

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.

Accreditation Statements

In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

For Physicians

Medscape, LLC designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Medscape, LLC staff have disclosed that they have no relevant financial relationships.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

Read the target audience, learning objectives, and author disclosures.
Study the educational content online or printed out.
Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

From Medscape Education Oncology

CME / ABIM MOC

Clinical Pearls on the Management of Immune-Mediated AEs Affecting the Liver

Authors: Joshua Bauml, MD; Richard Kalman, MDFaculty and Disclosures

THIS ACTIVITY HAS EXPIRED FOR CREDIT

CME / ABIM MOC Released: 5/23/2018

Valid for credit through: 5/23/2019, 11:59 PM EST

processing....

PDF téléchargeable en français

« Return to: Clinical Pearls on the Management of Immune-Mediated AEs Affecting the Liver

Download Slides

PDF Downloads

Print
Like Tweet

References

Faculty and Disclosures

Moderator

Joshua Bauml, MD

Panelist

Richard S. Kalman, MD

Editor

Charlotte Warren

CME Reviewer

Amy H. Seung, PharmD, BCOP

CME / ABIM MOC

Clinical Pearls on the Management of Immune-Mediated AEs Affecting the Liver

Target Audience and Goal Statement

Disclosures

Moderator

Joshua Bauml, MD

Panelist

Richard S. Kalman, MD

Editor

Charlotte Warren

CME Reviewer

Amy H. Seung, PharmD, BCOP

Accreditation Statements

For Physicians

Instructions for Participation and Credit

Clinical Pearls on the Management of Immune-Mediated AEs Affecting the Liver

PDF téléchargeable en français

PDF Downloads